In conclusion, our study revealed that cetuximab enhances the cytotoxic effect of RSL3 on KRAS mutant CRC cells, and we demonstrated a novel mechanism involved in the anticancer effect of cetuximab on KRAS mutant CRC. This evidence concerns the gene KRAS and colorectal carcinoma.